Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study
Background In real-world studies, it is unclear whether galcanezumab has a significant effect in the first week after administration. Methods We retrospectively assessed 55 high-frequency episodic migraine (HFEM) and chronic migraine patients who received three galcanezumab doses. Mean changes in the numbers of weekly migraine days (WMDs) during month 1 and migraine days per month (MMDs) after 1–3 months of treatment were obtained. Clinical factors related to a ≥ 50% response rate (RR) at month 3 were analyzed. The prediction of ≥ 50% responders at month 3 using different weekly RRs at week 1 (W1) was evaluated. The RR at W1 was calculated with the following formula: RR (%) = 100 − [(WMDs at W1/baseline WMD) × 100]. Results The number of MMDs significantly improved from baseline to 1, 2 and 3 months. The ≥ 50% RR was 50.9% at 3 months. The number of WMDs decreased significantly from baseline to week 1 (− 1.6 ± 1.7 days), week 2 (− 1.2 ± 1.6 days), week 3 (− 1.0 ± 1.3 days), and week 4 (− 1.1 ± 1.6 days) during month 1. The RR at W1 was largest (44.6 ± 42.2%). The ≥ 30%, ≥ 50% and ≥ 75% RRs at W1 were significantly predictive of a ≥ 50% RR at 3 months. Logistic regression analysis predicting a ≥ 50% RR at month 3 showed that the RR at W1 was the sole contributing factor. Conclusion In our study, galcanezumab showed a significant effect in the first week after administration, and the RR at W1 could predict the RR at 3 months..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:270 |
|---|---|
| Enthalten in: |
Journal of neurology - 270(2023), 9 vom: 23. Mai, Seite 4377-4384 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Suzuki, Keisuke [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Calcitonin gene-related peptide |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00415-023-11788-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144960089 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144960089 | ||
| 003 | DE-627 | ||
| 005 | 20240118101957.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00415-023-11788-x |2 doi | |
| 035 | |a (DE-627)OLC2144960089 | ||
| 035 | |a (DE-He213)s00415-023-11788-x-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Suzuki, Keisuke |e verfasserin |0 (orcid)0000-0003-0320-8993 |4 aut | |
| 245 | 1 | 0 | |a Could efficacy at 1 week after galcanezumab administration for patients with migraine predict responders at 3 months? A real world study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Background In real-world studies, it is unclear whether galcanezumab has a significant effect in the first week after administration. Methods We retrospectively assessed 55 high-frequency episodic migraine (HFEM) and chronic migraine patients who received three galcanezumab doses. Mean changes in the numbers of weekly migraine days (WMDs) during month 1 and migraine days per month (MMDs) after 1–3 months of treatment were obtained. Clinical factors related to a ≥ 50% response rate (RR) at month 3 were analyzed. The prediction of ≥ 50% responders at month 3 using different weekly RRs at week 1 (W1) was evaluated. The RR at W1 was calculated with the following formula: RR (%) = 100 − [(WMDs at W1/baseline WMD) × 100]. Results The number of MMDs significantly improved from baseline to 1, 2 and 3 months. The ≥ 50% RR was 50.9% at 3 months. The number of WMDs decreased significantly from baseline to week 1 (− 1.6 ± 1.7 days), week 2 (− 1.2 ± 1.6 days), week 3 (− 1.0 ± 1.3 days), and week 4 (− 1.1 ± 1.6 days) during month 1. The RR at W1 was largest (44.6 ± 42.2%). The ≥ 30%, ≥ 50% and ≥ 75% RRs at W1 were significantly predictive of a ≥ 50% RR at 3 months. Logistic regression analysis predicting a ≥ 50% RR at month 3 showed that the RR at W1 was the sole contributing factor. Conclusion In our study, galcanezumab showed a significant effect in the first week after administration, and the RR at W1 could predict the RR at 3 months. | ||
| 650 | 4 | |a Migraine | |
| 650 | 4 | |a Weekly migraine days | |
| 650 | 4 | |a Galcanezumab | |
| 650 | 4 | |a Calcitonin gene-related peptide | |
| 700 | 1 | |a Suzuki, Shiho |4 aut | |
| 700 | 1 | |a Shiina, Tomohiko |4 aut | |
| 700 | 1 | |a Haruyama, Yasuo |4 aut | |
| 700 | 1 | |a Fujita, Hiroaki |4 aut | |
| 700 | 1 | |a Funakoshi, Kei |4 aut | |
| 700 | 1 | |a Hirata, Koichi |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neurology |d Springer Berlin Heidelberg, 1974 |g 270(2023), 9 vom: 23. Mai, Seite 4377-4384 |w (DE-627)129403954 |w (DE-600)187050-6 |w (DE-576)014785528 |x 0340-5354 |7 nnns |
| 773 | 1 | 8 | |g volume:270 |g year:2023 |g number:9 |g day:23 |g month:05 |g pages:4377-4384 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00415-023-11788-x |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_2410 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 270 |j 2023 |e 9 |b 23 |c 05 |h 4377-4384 | ||